UNIGE document Scientific Article
previous document  unige:138506  next document
add to browser collection
Title

Validation of a commercially available SARS-CoV-2 serological immunoassay

Authors
Zimmer, Gert
show hidden authors show all authors [1 - 19]
Collaboration
Published in Clinical Microbiology and Infection. 2020
Abstract Objectives: To validate the diagnostic accuracy of a Euroimmun SARS-CoV-2 IgG and IgA immunoassay for COVID-19. Methods: In this unmatched (1:2) case-control validation study, we used sera of 181 laboratory-confirmed SARS-CoV-2 cases and 326 controls collected before SARS-CoV-2 emergence. Diagnostic accuracy of the immunoassay was assessed against a whole spike protein-based recombinant immunofluorescence assay (rIFA) by receiver operating characteristic (ROC) analyses. Discrepant cases between ELISA and rIFA were further tested by pseudo-neutralization assay.
Keywords COVID-19ELISAPseudovirus neutralisation assayRecombinant immunofluorescence assaySARS-CoV-2Serological AssaysSerological testing strategy
Identifiers
PMID: 32603801
Full text
Structures
Citation
(ISO format)
MEYER, Benjamin et al. Validation of a commercially available SARS-CoV-2 serological immunoassay. In: Clinical Microbiology and Infection, 2020. doi: 10.1016/j.cmi.2020.06.024 https://archive-ouverte.unige.ch/unige:138506

46 hits

16 downloads

Update

Deposited on : 2020-07-17

Export document
Format :
Citation style :